Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283594 | 0.85 | KDM4E (0.50) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL14207934 | 0.85 | MMP13 (0.48) | LMNAPOLBMMP13ALDH1A1PTGS1 | |
| SCHEMBL12672485 | 0.83 | MMP13 (0.47) | LMNAMMP13ALDH1A1MEN1KMT2A | |
| SCHEMBL909104 | 0.83 | CA2 (0.47) | KDM4ELMNAPOLBMMP13ALDH1A1 | |
| SCHEMBL969589 | 0.82 | HPGD (0.55) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL154429 | 0.82 | KDM4E (0.55) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL14430305 | 0.81 | FFAR4 (0.54) | FFAR4 | |
| SCHEMBL16148556 | 0.80 | MMP13 (0.44) | LMNAMMP13ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2530255 | 0.80 | HPGD (0.53) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL4659342 | 0.80 | MMP13 (0.48) | LMNAMMP13ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| WO-2023235929-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USES THEREOF | NOXOPHARM LIMITED (AU) | 2023-12-14 | — | — | WO | disclosed |
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | SAINT LOUIS UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2021252505-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2021-12-16 | — | — | WO | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1887000-A1 | ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON | Shionogi Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | KDM4E 3525/4885HPGD 2659/4885HSD17B10 4222/4885 |
| US-20230212172-A1 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | AADAC, PAICS, PNPO | KDM4E 3745/4885HPGD 1074/4885HSD17B10 3946/4885 |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | CYP2A7, CYP4X1, HAX1 | KDM4E 1460/4885HPGD 3687/4885HSD17B10 47/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | KDM4E 3670/4885HPGD 144/4885HSD17B10 362/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | KDM4E 927/4885HPGD 214/4885HSD17B10 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.